Kornimate/medical-research-clean huggingface dataset:
a new formulation of intravenous paracetamol for fever management

Conditions: Fever

Summary: the efficacy of intravenous paracetamol has never been compared with other drugs for the management of fever due to infections. available data come from clinical studies conducted in healthy volunteers subject to experimental endotoxemia. the present study compares the efficacy of the new αpotel μax® formulation versus placebo for the management of fever of infectious origin.

a new formulation of paracetamol for intravenous administration has been manufactured in greece by the industry uni-pharma (αpotel μax®). according to this new formulation, 1g of paracetamol is provided as a flask diluted into 100ml volume with the possibility of immediate connection with the infusion device of the patient. this formulation provides the advantage of a dilution ready-to-use which equals considerable financial benefit; nursing staff is not pre-occupied with the preparation of dilutions and the amount of consumables required for the preparation of this dilution is significantly decreased. taking into consideration that the antipyretic effect of intravenous paracetamol has never been studied compared with other agents in patients and available data come from studies in volunteers with experimental endotoxemia, the present study compares the efficacy of the new αpotel μax® formulation versus placebo for the management of fever of infectious origin (fever due to infection of the upper respiratory tract, of the lower respiratory tract, acute pyelonephritis or of the skin and soft tissues).

Eligibility criteria:
inclusion criteria: 1. written informed consent by the patient 2. patient of either gender 3. age equal to or greater than 18 years old 4. fever onset less than 24 hours 5. body temperature greater than or equal to 38.50c. 6. infection of the upper respiratory tract or of the lower respiratory tract or acute pyelonephritis or infection of the skin and soft tissues that can explain fever onset. exclusion criteria: 1. age below 18 years old 2. denial for written consent 3. intake of paracetamol for any reason either orally or intravenously or intramuscularly the last 12 hours 4. intake of any non-steroidal anti-inflammatory drug the last 8 hours 5. intake of any steroidal anti-inflammatory drug the last 12 hours 6. history of liver cirrhosis 7. serum creatinine greater than 3 mg/dl 8. aspartate aminotransferase more than 3 times greater than the upper normal limit for the hospital lab 9. known allergy to non-steroidal anti-inflammatory drugs or to paracetamol 10. pregnancy or lactation 11. active bleeding of the upper or the lower gastrointestinal tract 12. thrombocytopenia defined as any absolute platelet count below 50000/mm3.

Keywords: paracetamol management of fever infections
b7-h3 nir imaging for osteosarcoma surgery

Conditions: Osteosarcoma; Resection Margins; B7-H3 Probe; Local Recurrence

Summary: complete removal of all tumor tissue with a wide surgical margin is essential for the treatment of osteosarcoma (os). however, it's difficult, sometimes impossible, to achieve due to the invisible small satellite lesions and blurry tumor boundaries. besides, intraoperative frozen-section analysis of resection margins of os is often restricted by the hard tissues around os, which makes it impossible to know whether a negative margin is achieved. herein, based on the high expression of b7-h3 in os, a targeted probe b7h3-irdye800cw is synthesized by conjugating anti-b7h3 antibody and irdye800cw. this trial is aimed to investigate r0-resection rate and 2-y local recurrence rate after using this probe in musculoskeletal tumor surgery for osteosarcoma as well as the safety parameters of this probe in human.


Eligibility criteria:
inclusion criteria: * 1. patients with histologically confirmed osteosarcoma of the limbs. * 2. the patients has not undergone tumor resection. * 3. age between 18 and 60 years old. * 4. no prior systemic treatment for osteosarcoma. * 5. measurable disease as assessed by imaging studies (e.g., mri, ct). * 6. adequate bone marrow, liver, and renal function. * 7. written informed consent obtained from the patient. exclusion criteria: * 1. history of other malignancies within the past 5 years. * 2. pregnancy or lactation. * 3. known hypersensitivity to any component of the b7h3-based nir imaging agent. * 4. uncontrolled intercurrent illness that would preclude safe study participation. * 5. prior radiation therapy to the target lesion. * 6. any medical condition that would compromise the patient's ability to undergo surgery or comply with study procedures. * 7.patients not able to sign the informed consent.

Keywords: osteosarcoma resection margins b7-h3 targeted probe local recurrence rate
gene mutations in secondary pulmonary hypertension

Conditions: Chronic Thromboembolic Pulmonary Hypertension

Summary: as a pulmonary hypertension center, we have created a database that prospectively tracks patients with different forms of secondary pulmonary hypertension. records include genetic analysis, and clinical and hemodynamic profiles.


Eligibility criteria:
inclusion criteria: * diagnosis of cteph and patient consent exclusion criteria: * no patient consent
validity and reliability of the turkish version of the sydney swallow questionnaire

Conditions: Dysphagia, Oropharyngeal; Swallowing Disorder; Validation

Summary: purpose of the study is the validity and reliability of the turkish version of the sydney swallow questionnaire (ssq-t), so that it would be used as an assessment tool for turkish dysphagia patients. despite being translated and validated in many languages, there is no validated turkish version of ssq to measure the severity of oropharyngeal dysphagia.

the swallow function is a multidirectional process that depends on complex neuro-muscular network. the function can be evaluated using instrumental, such as fibreoptic endoscopic evaluation of swallowing (fees), videofluoroscopy, or well structured questionnaires. there are many questionnaire and scales for assessment of swallow but very few have been validated. the study will assess the construct validity and reliability of the turkish version of self-report symptom inventory as known as sydney swallow questionnaire. the investigators developed the turkish version of this questionnaire (ssq-t), according to the cross-cultural adaptation guidelines. two translators translated the ssq into turkish and a native english language speaker reverse-translated it into english. the back translation was sent to the original author for proofreading. the ssq questionnaire consisted of 17 basic questions related with dysphagia symptoms.

Eligibility criteria:
inclusion criteria: group 1: * able to speak, read, understand and write in turkish * history of dysphagia during 6 months * age between 18-80 years group 2: * able to speak, read, understand and write in turkish * healthy adults * age between 18-80 years old. exclusion criteria: * mental disorders * cognitive limitations * able not to speak, read, understand and write in turkish * underwent any surgery last a month * underwent laryngectomy/neck dissection/tracheostomy/neck radiotherapy * pregnancy * malignancies * out of age 18-80 years old.
effects of a reduction in kidney function on cardiovascular structure and function: a prospective study of kidney donors

Conditions: Chronic Kidney Disease

Summary: studies of patients with established kidney disease, even when this is mild, appear to show that they are at high risk of heart failure, stroke and sudden cardiac death. this may be because kidney disease causes stiffening of the arteries in the body which means that the heart and brain are damaged by high blood pressure. by studying patients before and after the removal of a kidney (uni-nephrectomy) for transplantation the investigators will find out for the first time in man the effect of an isolated reduction in kidney function on the structure and function of the arteries and heart. hypotheses. an isolated reduction in gfr occuring after surgical uni-nephrectomy is associated with long term adverse cardiac and vascular effects which include: 1. increased arterial stiffness and left ventricular mass 2. abnormalities in left ventricular systolic and diastolic function 3. increased oxidative stress, inflammation and collagen turnover


Eligibility criteria:
inclusion criteria: * potential kidney donor attending university hospital birmingham nhs foundation trust current nationally set exclusion criteria: * diabetes mellitus * atrial fibrillation * left ventricular dysfunction (ejection fraction \<40% on transthoracic echocardiography) * history of cardiovascular or pulmonary disease * evidence of hypertensive end-organ damage.

Keywords: chronic kidney disease left ventricular dysfunction diastolic dysfunction hypertension
intact abdominal aortic aneurysm repair in portugal

Conditions: Abdominal Aortic Aneurysm

Summary: abdominal aortic aneurysm (aaa) repairs registered in the hospitals administrative database of the national health service from 2000 to 2015 were retrospectively analyzed regarding demographics (age and gender) and type of repair (open surgery \[os\] or endovascular repair \[evar\]). rate and mortality were compared among three time periods: 2000-2004, 2005-2009 and 2010-2015.

all aaa interventions performed during the period 2000 to 2015 were retrospectively identified in a national health service (nhs) administrative database, the hospital morbidity database, formerly designated as diagnosis-related groups (drgs) database. this database was provided by the portuguese central health system administration (acss) and contains a registration of all hospitalizations (retrospective consecutive case entry) occurring in public hospitals in mainland portugal. each episode includes information about diagnoses (primary and secondary diagnoses) and medical or surgical procedures, both coded using the international classification of diseases, ninth revision, clinical modification (icd-9). all admissions considered have a primary diagnosis icd-9 codes for ruptured and non-ruptured aaa. the primary diagnosis of an episode represents the main condition investigated or treated during that hospital stay. the rate of the repair was calculated based on the episodes of care with the above-mentioned disease icd-9 codes plus the icd-9 procedure codes suitable for aaa repair. admissions with a primary diagnose of aaa that lacked a icd-9 procedure code suitable for aaa repair were excluded, assuming that no repair was performed during that hospital stay. general indication for iaaa repair in portugal are a maximum transverse diameter ≥5.5cm in men and ≥5.0 cm in women, as recommended by guidelines. the number of deaths accounted for all patients that fail to be discharged alive from the hospital admission where the repair took place, irrespective to the direct cause of death. the number of admissions for repair in which the patient died divided by the number of all admissions for repair was used as a proxy of in-hospital mortality due to iaaa. the number of resident population in each year under analysis was provided by the national institute of statistics (ine) from 2000 to 2015. resident population per year was used to calculate the rate of aaa repair and the death associated with aaa repair (thereafter mentioned as mortality to distinguish from the above-mentioned in-hospital mortality). death certificate with aaa-specific mortality was provided from the national institute of statistics (ine) from 2000 to 2015. ine data includes deaths outside the hospital besides those certificated at the hospitals. in both databases, patients \<50 years of age were excluded.

Eligibility criteria:
inclusion criteria: * patients submitted to abdominal aortic aneurysm repair in portugal from 2000-20015 exclusion criteria: * patients without abdominal aortic aneurysm
asymptomatic and pre-symptomatic transmission of sars-cov-2 in a community congregant setting

Conditions: COVID-19; SARS-CoV2 Infection

Summary: the overall aim of this study is to measure how transmission of covid-19 occurs in communities - including the role of super spreaders and/or identifying conditions that may increase transmission risk, with a focus on congregant situations. in order to identify how presence of symptoms and behavior affects the transmissibility of the virus, the investigators will measure sars-cov-2 in exhaled breath of asymptomatic and symptomatic persons using polyvinyl alcohol (pva) test strips embedded in face masks (face mask sampling- "fms") - an innovative, non-invasive method for detection of sars-cov-2 in exhaled air.


Eligibility criteria:
inclusion criteria: * individuals age ≥ 18 years of any gender tested positive for sars-cov-2 by a molecular reference test (pcr test or antigen test) \[index patients\] * individuals age ≥ 18 years and known to be contacts of the index patients \[contacts\] exclusion criteria: * \< age 18 years old, unable to wear a face mask due to underlying condition, not able to consent, pregnancy. in addition, signs of severe disease present at time of enrollment (e.g. difficulty breathing, pain when breathing, tightness of chest or developing irregular heart beat).

Keywords: covid-19 transmission sars-cov2 transmission
the relationship between microbiota and coronary ectasia

Conditions: Coronary Ectasia; Microbial Disease

Summary: introduction: it is now known that the microbiota is far beyond the microbial communities living in certain parts of our body and functions like a metabolic organ. in addition, the microbiota, through its metabolites, is involved in the pathophysiology or progression of a wide range of diseases, from atherosclerotic diseases to metabolic diseases and even neurological diseases. among these metabolites, trimethylamine n-oxide metabolite has been shown to be particularly effective on atherosclerotic heart diseases.


Eligibility criteria:
inclusion criteria: * over 18 years old * not having occlusive coronary artery disease * having coronary ectasia exclusion criteria: * patients with chronic kidney disease, * revascularized coronary artery disease, * previously documented critical coronary stenosis, * acute or chronic inflammatory disease, * rheumatologic disease, * known active malignant disease, * heart failure, * moderate-to-severe valvular pathology * patients who were on any steroid or immunosuppressive therapy

Keywords: microbiota endothelium
the effect of a gamified neuropathy management application on cancer behavior in cancer patients undergoing chemotherapy

Conditions: Cancer; Chemotherapy Induced Pain Neuropathy; Nursing; Gamification

Summary: this study will be conducted to determine the effect of a gamified neuropathy management application on cancer behavior in cancer patients undergoing chemotherapy.

cancer patients may experience treatment-related issues throughout their treatment process. chemotherapy-induced peripheral neuropathy is one of the symptoms that negatively affects patients' overall health status. peripheral neuropathy can occur during or after chemotherapy, leading to sensory, motor, and autonomic nerve damage. it is particularly common among cancer patients receiving taxane- and platinum-based chemotherapy. effective management of neuropathy is a crucial aspect of nursing care. here are some key points regarding this issue: pharmacological and non-pharmacological methods, lifestyle control, and nursing interventions are employed. the management of peripheral neuropathy can have a significant impact on the overall health and well-being of cancer patients undergoing chemotherapy. nurses play a vital role in this process by providing support that enhances patients' quality of life and improves treatment outcomes. gamification applications, which have recently started to be used in patient education, represent a contemporary approach. however, no studies have been found utilizing gamification specifically in patient education for cancer. for this reason, this study aims to contribute to patients' neuropathy management using a gamification application.

Eligibility criteria:
inclusion criteria: * undergoing chemotherapy treatment and have completed their first cycle. * literate (able to read and write). * able to use a smartphone. * aged between 18 and 65 years. * willing to participate in the study voluntarily. exclusion criteria: * participants who do not use the application during the study period * participants who fail to complete the data collection forms

Keywords: cancer chemotherapy induced pain neuropathy nursing gamification
suppression with empagliflozin as an alternative to high-fat low-carbohydrate diet for myocardial f-fluorodeoxyglucose positron emission tomography (fdg-pet) imaging

Conditions: Myocardial Suppression

Summary: the overall objective of this study is to assess if the empagliflozin has the potential to substitute the high fat low carb (hflc) diet for the preparation of cardiovascular fdg-pet studies.

the overall objective of this study is to assess if the sglt2 inhibitor empagliflozin has the potential to substitute the high fat low carb (hflc) diet for the preparation of cardiovascular fdg-pet studies. this study will evaluate if an acute administration of empagliflozin (tablets of 10 and/or 25 mg) combined with fasting can sufficiently increase the bhb levels, a proxy of myocardial fdg uptake.

Eligibility criteria:
inclusion criteria: 1. aged 18 to 70 years 2. ability to follow the hflc diet 3. ability to provide informed consent exclusion criteria: 1. treated with sglt2 inhibitors 2. history of hypersensitivity or allergy to empagliflozin 3. hypotension with blood pressure \<100/65 mmhg 4. strict vegan 5. pregnancy 6. breastfeeding 7. type i or type ii diabetes 8. renal failure with estimated glomerular filtration rate (egfr) \<60 ml/min/1.72m2 9. receiving steroids 10. history of diabetic ketoacidosis (dka) 11. history of hypoglycemia 12. any condition that, in the opinion of the investigator, could compromise the participation in the study
detection of oral and throat cancers using oralviome cancer testing system

Conditions: Oral Squamous Cell Carcinoma; Oropharynx Squamous Cell Carcinoma; Premalignant Lesion

Summary: to evaluate the design, safety and efficacy of oralviome cancer testing system in the early detection of oral and throat cancers using saliva metatranscriptomic analysis. this study will recruit only at existing clinical sites and will not use any additional clinical sites.

this is an observational study evaluating the design, safety and efficacy of oralviome cancer testing system in the early detection of oral and throat cancers using saliva metatranscriptomic. a total of 475 participants will be recruited, including 4 different cohorts: 1) cancer free patients, 2) patients with oral potentially malignant disease (opmd), 3) patients with oral squamous cell carcinoma (oscc), and 4) patients with oropharyngeal cancer (opc). oscc and opc participants will be recruited from secondary care facilities, opmd and cancer free participants will be recruited from primary care facilities. participants will complete health questionnaires and collect saliva samples using at home/ in clinic kits provided by viome. the duration of study participation will be 1 clinic visit for cancer free participants, and up to 1 year for those with oscc/opc/opmd.

Eligibility criteria:
inclusion criteria * signed informed consent obtained * 18 years and older * at a high risk of developing oral or throat cancer based on clinician's discretion exclusion criteria * pregnancy * use of fertility enhancing medications

Keywords: viome oral cancer detection oscc opmd-b opmd-pm opmd opv tobacco hpv
non invasive ventilation on peripheral muscle function and aerobic performance

Conditions: Chronic Obstructive Pulmonary Disease

Summary: background: non-invasive ventilation (niv) reduces respiratory load and demands on peripheral muscles. methods: this study aims to evaluate the acute effects of bi-level niv on peripheral muscle function during isokinetic exercise and aerobic performance in chronic obstructive pulmonary disease (copd) patients. this is a pilot crossover study performed with a non-probabilistic sample of 14 moderate to very severe copd patients. procedures carried out in two days. dyspnea, quality of life, lung function, respiratory muscle strength, functional capacity (6-minute walk test - 6mwt), and isokinetic assessment of the quadriceps were assessed. blood samples (lactate, lactate dehydrogenase, and creatine kinase concentration) were also collected. right after, niv was performed for 30 minutes (bi-level or placebo, according to randomization) followed by new blood sample collection, 6mwt, and isokinetic dynamometer tests. before and after evaluations, the subjective perception of dyspnea and fatigue in the lower limbs was quantified. after a wash-out period of seven days, participants returned, and all assessments were performed again.


Eligibility criteria:
inclusion criteria: * clinically stable copd patients (diagnosed according to the global initiative for obstructive lung disease), of both sexes, without exacerbation or changes in medication for at least one month before the study, and no dyspnea during daily activities (grades 2, 3, and 4 of the medical research council - mrc scale) were included. exclusion criteria: * those with a diagnosis of neoplasia, orthopedic or neurological conditions affecting exercise capacity, peripheral arterial obstructive disease, heart failure, kidney or liver disease, did not adapt, or failed to complete the study procedures, were excluded.

Keywords: copd skeletal muscle non-invasive ventilation
study to determine the effects of pre-warming on or patient temperatures and surgical outcomes

Conditions: Hypothermia

Summary: the application of active warming to patients whether awake or under general anesthesia has been proven safe in numerous studies and it is common practice to use warmers. the warmers are commonly used with both the supplied blankets and also with hospital blankets. subjects receiving standard care will not benefit from this study. subjects in the investigational group may benefit in several ways: * increased comfort in the pre-operative period by being warmer * decreased incidence of mild hypothermia * possible decreased incidence of transfusion with less bleeding * possible decreased pain and discomfort in the post-anesthesia care unit (pacu) * possible shorter stay in the pacu and overall length of stay (los) * possible decreased risk for surgical site infection


Eligibility criteria:
inclusion criteria: * elective or "urgent" surgery under general anesthesia * ≥19 years but ≤85 years of age * able to provide informed consent. exclusion criteria: * refusal of informed consent * metabolic derangement/drug therapy already affecting thermal homeostasis * preexisting hypothermia (\ 37.5 degreec) (oral) * surgical procedure anticipated to be longer than 6 hours or less than 1 hour * emergency (category 1a) surgery * patients undergoing exclusively spinal or epidural anesthesia * patients receiving aortic cross-clamping * patients receiving transdermal medications

Keywords: hypothermia surgical site infection opioid usage blood loss pain severity anxiety length of stay
study of metformin and s. baicalensis combination therapy in type 2 diabetes mellitus patients

Conditions: Diabetes Mellitus

Summary: the study is a pilot trial to investigate the effect of metformin and s. baicalensis combination therapy in type 2 diabetes mellitus patients.


Eligibility criteria:
inclusion criteria: * diagnosed as a diabetes mellitus patient at least 3 months ago on screening * treated with metformin of ≥ 500 mg/day over 3 months on screening * fasting glucose level of 110\~180 mg/dl or hba1c of 7.0\~9.0% on screening exclusion criteria: * with acute or chronic inflammation * treated with systemic corticosteroids within 4 weeks prior to the first administration of study medication * with heart failure, myocardial infarction, stroke, or other acute severe cardiovascular diseases * with acute or chronic renal failure or nephrotic syndrome * with impaired hepatic function. * drug or alcoholic abuser * pregnant or nursing woman